Airsculpt Technologies, Inc.
No enriched coverage for $AIRS in the last 7 days.
No SEC Form 4 filings for $AIRS in the last 30 days.
See all $AIRS insider activity →AirSculpt Technologies (AIRS) reported Q2 2026 revenue of $42.9M, down 3% from $44.0M a year earlier. Q2 case volume was 3,376, slightly down, while gross margin rose to 61.2%. Adjusted EBITDA was $4.9M. Full-year revenue guidance is $151M to $157M and Adjusted EBITDA $12M to $14M, revised lower on added marketing. Cash was $18.8M; debt was $44.2M.
U.S. stock futures were mixed Monday, with Dow futures down about 0.1%. Airsculpt Technologies (AIRS) fell in pre-market after Q2 results. Adjusted EPS was 1 cent, matching estimates, while sales were $42.9M versus $44.137M expected. FY2026 sales guidance was narrowed to $151M. Shares dropped 13.4% to $4.34.
U.S. stock index futures edged higher as investors weighed fading Middle East deal hopes and upcoming inflation data. Tenax Therapeutics shares fell 84.2% after Phase 3 TNX-103 missed endpoints. Sionna Therapeutics dropped 92.1% after Phase 2a SION-719 failed. MarineMax rose over 34% on a reported $1.5B Safe Harbor Marinas buyout. AAON, Silence, Dole, and AirSculpt also moved premarket on updates.
Recent AIRS coverage spans financial news, earnings and market movers.
Guidance cut tied to higher marketing spend, alongside modest Q3 revenue softness and continued same-center case growth, frames a near-term margin tradeoff.
The earnings miss on sales and a narrow FY2026 sales guidance update are driving a sharp pre-market selloff.
Weaker operating metrics and profitability deterioration are direct negative catalysts for AIRS.
Guidance reset on revenue range and profitability outlook is the primary driver of near-term repricing risk for AIRS.
Guidance reaffirmed for revenue but profitability outlook reduced, alongside modest same-center volume stability and a liquidity/term-loan amendment.
alphai scores every news story that mentions AIRS with an AI model for sentiment and relevance, and aggregates insider trades from Airsculpt Technologies, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
AirSculpt Technologies (AIRS) reported Q2 2026 revenue of $42.9M, down 3% from $44.0M a year earlier. Q2 case volume was 3,376, slightly down, while gross margin rose to 61.2%. Adjusted EBITDA was $4.9M. Full-year revenue guidance is $151M to $157M and Adjusted EBITDA $12M to $14M, revised lower on added marketing. Cash was $18.8M; debt was $44.2M.
6 min readU.S. stock futures were mixed Monday, with Dow futures down about 0.1%. Airsculpt Technologies (AIRS) fell in pre-market after Q2 results. Adjusted EPS was 1 cent, matching estimates, while sales were $42.9M versus $44.137M expected. FY2026 sales guidance was narrowed to $151M. Shares dropped 13.4% to $4.34.
2 min readU.S. stock index futures edged higher as investors weighed fading Middle East deal hopes and upcoming inflation data. Tenax Therapeutics shares fell 84.2% after Phase 3 TNX-103 missed endpoints. Sionna Therapeutics dropped 92.1% after Phase 2a SION-719 failed. MarineMax rose over 34% on a reported $1.5B Safe Harbor Marinas buyout. AAON, Silence, Dole, and AirSculpt also moved premarket on updates.
7 min readInvesting.com reports AirSculpt Technologies (AIRS) shares fell about 18.4% in pre-open after its Q2 fiscal 2026 earnings. Revenue was $42.9M, down 3% YoY, with net loss of $1.1M and Adjusted EBITDA $4.9M (11.5% margin). Guidance was revised to the lower end of $151–$157M revenue and Adjusted EBITDA $12–$14M.
4 min readAirsculpt Technologies, Inc. (AIRS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 AirSculpt Technologies Reports Second Quarter Fiscal 2026 Results Same Center Cases Up 1% for the Second Consecutive Quarter MIAMI BEACH, Fla., August 10, 2026 (GLOBE NEWSWIRE) – AirSculpt Technologies, Inc. (NASDAQ:AIRS)(“AirSculpt” or the “Company”), a national pro
6 min readThis article provides a stock quote for AirSculpt Technologies, Inc. (NASDAQ:AIRS), showing its current trading price, volume, and performance metrics. It also includes recent news headlines about the company's Q1 earnings, sales rebound with GLP-1 tailwind for body contouring growth, and previous financial reports and analyst insights. The information covers detailed quote data, historical prices, and frequently asked questions about the stock.
3 min readJorey Chernett, a more than 10% owner of Airsculpt Technologies, Inc. (AIRS), purchased an additional 40,000 shares of common stock at a weighted average price of $2.54 per share, increasing his direct holdings to over 7 million shares. Concurrently, short call options on 400,400 underlying shares with exercise prices of $4.00 and $5.00 expired unexercised because the market price was below the strike prices, with no consideration received. This transaction signals increased equity exposure by a significant shareholder.
2 min readJorey Chernett, a ten-percent owner of Airsculpt Technologies (NASDAQ:AIRS), acquired 105,848 shares of common stock for $257,210 on March 16, 2026. This purchase occurred despite the stock being down 51% over six months, though it surged 36% in the preceding week. The company recently reported $151.8 million in revenue for fiscal year 2025 and is delaying its annual report filing to accurately classify inter-company transactions.
4 min readAirSculpt Technologies, Inc. (AIRS) saw its stock jump over 51% on March 16, 2026, following a 12b-25 filing and preliminary 2025 revenue of $151.80 million. Investors are now focused on the upcoming earnings report on March 20, 2026, which will provide more clarity on finances and liquidity. Meyka AI projects a yearly target of $3.74 for AIRS, suggesting a 33.09% upside, while highlighting risks such as debt and negative EPS.
3 min readThe most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down.
4 min read
